Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rozemarijn S Verhoeven is active.

Publication


Featured researches published by Rozemarijn S Verhoeven.


Journal of Ocular Pharmacology and Therapeutics | 2009

Ocular Surface Distribution and Pharmacokinetics of a Novel Ophthalmic 1% Azithromycin Formulation

Esen Karamursel Akpek; Jason Vittitow; Rozemarijn S Verhoeven; Kurt Brubaker; Thierry Amar; Kendall Powell; José Luis Boyer; Christopher Crean

PURPOSE To investigate the ocular distribution of 1% azithromycin ophthalmic solution and the effect of polycarbophil-based mucoadhesive formulation on ocular tissue levels of azithromycin after single and multiple topical administrations in the rabbit eye. METHODS Rabbits were treated with either a single administration of 1% azithromycin solution with or without polycarbophil, or with multiple administrations of 1% azithromycin solution in polycarbophil. Drug concentrations were measured using LC/MS/MS. Conjunctiva, cornea, aqueous humor, and tear samples were analyzed over a period of 144 h after a single administration of azithromycin with or without polycarbophil. Eyelid, conjunctiva, cornea, aqueous humor, and tear samples were collected over a period of 288 h during and after multiple administrations of azithromycin. RESULTS Azithromycin was rapidly absorbed and distributed in the ocular tissues, reaching within 5 min, concentrations of 10,539 microg/mL in tear film, 108 microg/g in conjunctiva, and 40 microg/g in the cornea. The drug demonstrated tissue-specific half-lives of 15, 63, and 67 h, respectively. Following multiple administrations, the drug gradually accumulated. The polycarbophil formulation increased the bioavailability of the drug, producing peak concentrations that were between 5- and 12-fold higher than those without polycarbophil. Azithromycin also distributed rapidly in the eyelids, reaching peak concentrations of 180 mug/g at the end of the 7-day treatment, and was eliminated with a half-life of 125 h. Six days after treatment was discontinued, eyelid levels of azithromycin were above 40 microg/g. CONCLUSIONS Sustained and high concentrations were encountered with 7-day approved administration of 1% azithromycin formulation (AzaSite, Inspire Pharmaceuticals, Inc., Durham, NC) within all ocular surface tissues, particularly the lids. Many ocular surface disorders involving the tear film, eyelids, and adnexal structures are associated with chronic, low-grade bacterial infection and may potentially lead to decreased vision secondary to corneal scarring. Various topical antibiotic and steroid combinations with or without oral tetracyclines are commonly used with variable clinical response and known potential side effects. The clinical relevance of this study is unknown; however, the long-lasting antibacterial and additional anti-inflammatory properties of topical azithromycin might offer an effective alternative treatment option and should be explored further in clinical studies.


Investigative Ophthalmology & Visual Science | 2014

Intraocular Distribution and Targeting of Triamcinolone Acetonide Suspension Administered Into the Suprachoroidal Space

Henry F. Edelhauser; Rozemarijn S Verhoeven; Brian Burke; Craig B Struble; Samirkumar R. Patel


Investigative Ophthalmology & Visual Science | 2017

In vitro and In vivo Sustained Release of Dexamethasone from Intravitreal Implants

Janet Tully; Mari Yang; Stuart Williams; Sanjib Das; Rozemarijn S Verhoeven; RiLee Robeson; Rhett M. Schiffman; Benjamin R. Yerxa


Archive | 2016

Implant for treatment of an ocular condition

Andres Garcia; Rozemarijn S Verhoeven; Tomas Navratil; Rhett Schiffman


Investigative Ophthalmology & Visual Science | 2016

A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit

Rozemarijn S Verhoeven; RiLee Robeson; Andres Garcia; Brian C. Gilger; David Culp; Craig B Struble; Lee Hamm; Thomas Grizzle; Tomas Navratil; Rhett M. Schiffman


Investigative Ophthalmology & Visual Science | 2016

Precision Size and Shape Extended Release Intravitreal Dexamethasone Implants

Sanjib Das; Stuart Williams; Janet Tully; Rozemarijn S Verhoeven; Mari Yang; Tomas Navratil; Rhett M. Schiffman


Investigative Ophthalmology & Visual Science | 2016

In vitro and In vivo Sustained Release of Dexamethasone from a PRINT Microparticle Suspension

Melissa Sandahl; Melissa Hernandez; Janet Tully; Gary Owens; Rozemarijn S Verhoeven; RiLee Robeson; Stuart Williams; Rhett M. Schiffman


Investigative Ophthalmology & Visual Science | 2016

A 6-Week Toxicity and Toxicokinetics Study of a Single Bilateral Intracameral Administration of ENV905 (difluprednate) Ophthalmic Implant in New Zealand White Rabbits

RiLee Robeson; Rozemarijn S Verhoeven; Andres Garcia; Paul E. Miller; J. M. Miller; Tomas Navratil; Rhett M. Schiffman


Investigative Ophthalmology & Visual Science | 2015

EXTENDED RELEASE BEVACIZUMAB INTRAVITREAL IMPLANT IS WELL TOLERATED IN THE AFRICAN GREEN MONKEY

Rozemarijn S Verhoeven; Stuart Williams; Jinny Conley; Gary Owens; Matthew S. Lawrence; Tomas Navratil; Benjamin R. Yerxa


Investigative Ophthalmology & Visual Science | 2014

Safety and toxicokinetics of suprachoroidal space (SCS) injections of CLS1001 (triamcinolone acetonide, TA) in albino rabbits

Glenn Noronha; Henry F. Edelhauser; Samir C. Patel; Brian Burke; Rozemarijn S Verhoeven

Collaboration


Dive into the Rozemarijn S Verhoeven's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Samirkumar R. Patel

Georgia Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Stuart Williams

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge